Natco Pharma

Natco Pharma is a pharmaceutical company that manufactures and markets affordable medicines, adhering to global standards. Its primary focus is on specialty medicines, with a strong presence in Oncology and Hepatology treatment areas. The company's core business lies in Active Pharmaceutical Ingredients (APIs), operating primarily in the pharmaceutical segment.

Rajeev Nannapaneni

Vice Chairman and CEO

7 past transactions

Egenesis

Series D in 2024
Egenesis Inc. is a biotechnology company focused on gene editing and genome engineering to create human transplantable organs, tissues, and cells. Established in 2015 and headquartered in Cambridge, Massachusetts, with an additional office in New York City, Egenesis aims to address the global organ shortage by developing solid organs and therapeutic cell transplantation solutions for various diseases. The company utilizes a gene editing platform that incorporates techniques such as single-cell cloning and somatic cell nuclear transfer, which are essential for creating human-compatible organ tissues and cells. Egenesis is particularly engaged in advancing programs related to kidney and islet cell transplantation, striving to provide alternative treatment options for patients with life-threatening conditions.

Cellogen Therapeutics

Corporate Round in 2024
Cellogen Therapeutics is a biotechnology company focused on developing innovative cell therapy-based solutions for the healthcare sector. The company employs advanced cellular engineering techniques and gene therapy to address a range of conditions, including hematological malignancies, solid tumors, and hemoglobinopathies. Through its work, Cellogen Therapeutics aims to provide effective CAR-T cell-based therapies for the treatment of cancer and metabolic diseases, delivering convenient and cost-effective solutions to healthcare providers and patients.

Pee Safe

Series B in 2023
Founded in 2013, Pee Safe specializes in personal hygiene products designed to maintain cleanliness and promote health. Initially known for its toilet seat sanitizer, the company has since expanded into various categories including feminine hygiene products, men's intimate care, hand hygiene solutions, face masks, and air purifying mists.

Eyestem

Series A in 2022
Eyestem is a biotechnology company focused on developing cell replacement therapies for treating incurable diseases. Its platform aims to generate consistent, high-quality cells derived from induced pluripotent stem cells, initially targeting conditions like dry age-related macular degeneration by replacing damaged photoreceptor cells in the eye.

Dash Pharmaceuticals

Acquisition in 2022
Dash Pharmaceuticals is a pharmaceutical company based in New Jersey, specializing in the sales, marketing, and distribution of generic drugs for the United States market. The company is involved in co-developing and licensing pharmaceutical products, which include nutritional and dietary supplements, vitamins, and topical treatments. Dash Pharmaceuticals markets and distributes these products under its own label, offering a variety of dosage forms to meet consumer needs. Through its comprehensive approach, the company aims to enhance access to essential medications and health products within the U.S. healthcare landscape.

CION Cancer Clinics

Series A in 2019
CION Cancer Clinics operates a network of day-care cancer treatment centers in Telangana and Andhra Pradesh, focusing on providing precise and individualized care for cancer patients. The clinics offer a range of services including treatment, detection, and awareness of cancer diseases, aimed at empowering patients to take control of their health. By providing essential support services and information, CION Cancer Clinics enables patients to receive not only medical assistance but also companionship and empathy throughout their recovery journey.

PACE Hospitals

Seed Round in 2017
PACE Hospitals operates a hospital chain that provides quality care for a wide range of tertiary healthcare services with personalized and ethical next-gen medicare. PACE delivers advanced procedures at a fraction of the international costs through relentless research and innovation. PACE Hospitals focuses on tertiary care services in the field of medical gastroenterology, surgical gastroenterology, hepatology, nephrology, urology, oncology, orthopedics, pulmonology, gynecology, ENT, cardiology, general medicine & diabetology, endocrinology, general surgery, critical care, cosmetic & plastic surgery, dermatology, neurology, neurosurgery, psychiatry, rheumatology, and andrology.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.